Mankind Pharma announced robust financial results for the second quarter and first half of FY27. Revenue grew 17% YoY to ₹4,338 crore in Q2 FY27, driven by strong domestic business performance. EBITDA saw a significant increase of 27% YoY, reaching ₹1,175 crore, with margins improving by 210 bps to 27.1%. PAT also surged by 38% YoY. The company highlighted strong growth in its chronic and acute therapy areas and strategic acquisitions.
Mankind Pharma Reports Strong Q2 FY27 Performance
Mankind Pharma has announced its financial results for the second quarter and half year ended September 30, 2026. The company reported a strong revenue growth of 17% year-over-year, amounting to ₹4,338 crore for Q2 FY27. This performance was largely propelled by a robust 16% growth in its domestic business.
Key Financial Highlights (Q2 FY27)
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increased by 27% year-over-year to ₹1,175 crore. The EBITDA margin improved significantly by 210 basis points to 27.1%. Profit After Tax (PAT) also demonstrated substantial growth, rising by 38% year-over-year. Domestic revenue for the quarter stood at ₹3,657 crore, up 14.8%, while exports grew by 32.7% to ₹681 crore.
Half-Yearly Performance (H1 FY27)
For the first half of FY27, Mankind Pharma’s revenue from operations reached ₹8,368 crore, marking a 15.1% increase compared to the same period last year. EBITDA for H1 FY27 was ₹2,235 crore, up 26.0%, with EBITDA margins at 26.7%. PAT for the half-year grew by 33.7% to ₹1,290 crore. Domestic revenue for H1 FY27 was ₹7,082 crore (up 12.7%), and exports increased by 31.0% to ₹1,286 crore.
Drivers of Growth
Mr. Rajeev Juneja, Vice Chairman & Managing Director, highlighted that revenue grew approximately 17% YoY with EBITDA margins improving by 210 bps. The strong domestic business growth of 15.9% was driven by key therapy areas. The company experienced mid-teen growth in Mankind Domestic with particular strength in Cardiac (19% growth) and Anti-diabetes (16% growth). Acute therapies also saw significant gains, with Gastro growing at 19% and VMN at 26%. The specialty business also contributed with steady double-digit growth.
International and Strategic Developments
International business reported a substantial growth of 33%. The company also announced its strategic acquisition of Armed Cell Therapeutics, marking an entry into Next-Generation CAR-T therapies and strengthening its research and development capabilities for future growth.
Consumer Healthcare Performance
The Consumer Healthcare business saw revenue growth impacted by slower industry offtake and regional factors. Despite this, Mankind Pharma gained market share in key brands like Manforce and Preganews. The MT & E-Com share increased to 18% in Q2 FY27 from 12% in Q2 FY26, supported by a 55% growth.
Source: BSE
